Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)-Reference-Cited by-同舟云学术

Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)

Published:2019-10-13 Issue:3 Volume:22 Page:458-462
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Cho Kyu Yong¹²^ORCID,Nomoto Hiroshi¹,Nakamura Akinobu¹^ORCID,Kawata Shinichiro¹,Sugawara Hajime³,Takeuchi Jun⁴,Nagai So⁵,Tsuchida Kazuhisa¹,Omori Kazuno¹^ORCID,Yokoyama Hiroki⁶,Manda Naoki⁷,Kurihara Yoshio⁸,Aoki Shin⁹,Atsumi Tatsuya¹,Miyoshi Hideaki¹¹⁰

Affiliation:

1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of MedicineHokkaido University Sapporo Japan

2. Clinical Research and Medical Innovation CentreHokkaido University Hospital Sapporo Japan

3. Third Department of Internal MedicineHokkaido P.W.F.A.C Obihiro‐Kosei General Hospital Obihiro Japan

4. Sapporo Diabetes and Thyroid Clinic Sapporo Japan

5. Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical CentreNTT East Corporation Sapporo Japan

6. Department of Internal MedicineJiyugaoka Medical Clinic Obihiro Japan

7. Department of Diabetes CentreManda Memorial Hospital Sapporo Japan

8. Kurihara Clinic Sapporo Japan

9. Aoki Clinic Sapporo Japan

10. Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of MedicineHokkaido University Sapporo Japan

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13879

Reference15 articles.

1. Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes

2. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics

3. Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes

4. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

5. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study);Journal of Diabetes Research;2024-01-05

2. Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet;Cureus;2022-10-17

3. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management;Cardiovascular Diabetology;2022-05-25

4. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan;Advances in Therapy;2022-02-09

5. Acute effect of add‐on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24‐hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase‐4 inhibitors;International Journal of Clinical Practice;2021-08-19